FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2742460075> ?p ?o ?g. }

• W2742460075 endingPage "72620" @default.
• W2742460075 startingPage "72613" @default.
• W2742460075 abstract "// Andreas Schicho 1 , Philippe L. Pereira 2 , Michael Haimerl 1 , Christoph Niessen 1 , Katharina Michalik 1 , Lukas P. Beyer 1 , Christian Stroszczynski 1 and Philipp Wiggermann 1 1 Department of Radiology, University Hospital Regensburg, Regensburg, Germany 2 Department of Radiology, Minimal-Invasive Therapies and Nuclear Medicine, SLK Kliniken Heilbronn, Heilbronn, Germany Correspondence to: Andreas Schicho, email: andreas.schicho@ukr.de Keywords: TACE, HCC, embolization, degradable starch microspheres, safety Received: February 13, 2017      Accepted: July 14, 2017      Published: August 07, 2017 ABSTRACT Background: Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related death worldwide. The majority of HCCs are diagnosed in a stage that is not eligible for curative resection. For intermediate stage HCC, transarterial chemoembolization (TACE) is the recommended treatment. We evaluated the safety and efficacy of DSM (degradable starch microspheres) as embolic agent in transarterial chemoembolization (TACE) for the treatment of intermediate stage, non-resectable hepatocellular carcinoma (HCC). Methods and Findings: A national, multi-center observational study on the safety and efficacy of DSM-TACE for the treatment of intermediate HCC was conducted. The recruitment period for the study was from January 2010 to June 2014. The primary endpoints were safety and treatment response according to the mRECIST criteria. A total of 179 DSM-TACE procedures in 50 patients were included in the analysis. The therapeutic efficacy assessed with mRECIST was as follows: complete response (n=1; 2 %), 21 partial response (42 %), 13 stable disease (26 %), 9 progressive disease (18 %), and 6 incomplete data (12 %). Thus, the objective response rate was 44% (n=22) and disease control rate was 70% (n=35). A total of 76 immediate adverse events (AE) and 2 severe adverse events (SAE) were recorded. Forty-eight percent of patients (n=24) did not encounter any immediate AE/SAE. Between treatments, a total of 66 AE and one SAE were recorded. Twenty-four patients (48 %) did not encounter any AE/SAE in between treatments. Conclusion: The use of DSM as a TACE embolic agent appears to be safe for the treatment of HCC and has promising efficacy." @default.
• W2742460075 created "2017-08-17" @default.
• W2742460075 creator A5007644263 @default.
• W2742460075 creator A5018266029 @default.
• W2742460075 creator A5028516114 @default.
• W2742460075 creator A5038837133 @default.
• W2742460075 creator A5043341174 @default.
• W2742460075 creator A5046219444 @default.
• W2742460075 creator A5059066561 @default.
• W2742460075 creator A5081930085 @default.
• W2742460075 date "2017-08-07" @default.
• W2742460075 modified "2023-10-17" @default.
• W2742460075 title "Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy" @default.
• W2742460075 cites W1568134792 @default.
• W2742460075 cites W1592179502 @default.
• W2742460075 cites W1930828223 @default.
• W2742460075 cites W1975154077 @default.
• W2742460075 cites W1996703005 @default.
• W2742460075 cites W2010265466 @default.
• W2742460075 cites W2060428561 @default.
• W2742460075 cites W2067593747 @default.
• W2742460075 cites W2079586464 @default.
• W2742460075 cites W2092759077 @default.
• W2742460075 cites W2104274330 @default.
• W2742460075 cites W2105831274 @default.
• W2742460075 cites W2125763116 @default.
• W2742460075 cites W2131963150 @default.
• W2742460075 cites W2133093305 @default.
• W2742460075 cites W2138059780 @default.
• W2742460075 cites W2236150109 @default.
• W2742460075 cites W2289095651 @default.
• W2742460075 cites W2301188205 @default.
• W2742460075 cites W2414135110 @default.
• W2742460075 cites W2564072667 @default.
• W2742460075 cites W4245403358 @default.
• W2742460075 doi "https://doi.org/10.18632/oncotarget.19997" @default.
• W2742460075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5641156" @default.
• W2742460075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29069813" @default.
• W2742460075 hasPublicationYear "2017" @default.
• W2742460075 type Work @default.
• W2742460075 sameAs 2742460075 @default.
• W2742460075 citedByCount "22" @default.
• W2742460075 countsByYear W27424600752018 @default.
• W2742460075 countsByYear W27424600752019 @default.
• W2742460075 countsByYear W27424600752020 @default.
• W2742460075 countsByYear W27424600752021 @default.
• W2742460075 countsByYear W27424600752022 @default.
• W2742460075 crossrefType "journal-article" @default.
• W2742460075 hasAuthorship W2742460075A5007644263 @default.
• W2742460075 hasAuthorship W2742460075A5018266029 @default.
• W2742460075 hasAuthorship W2742460075A5028516114 @default.
• W2742460075 hasAuthorship W2742460075A5038837133 @default.
• W2742460075 hasAuthorship W2742460075A5043341174 @default.
• W2742460075 hasAuthorship W2742460075A5046219444 @default.
• W2742460075 hasAuthorship W2742460075A5059066561 @default.
• W2742460075 hasAuthorship W2742460075A5081930085 @default.
• W2742460075 hasBestOaLocation W27424600751 @default.
• W2742460075 hasConcept C126322002 @default.
• W2742460075 hasConcept C143998085 @default.
• W2742460075 hasConcept C2778019345 @default.
• W2742460075 hasConcept C2778822529 @default.
• W2742460075 hasConcept C2779134260 @default.
• W2742460075 hasConcept C2779984678 @default.
• W2742460075 hasConcept C2780073493 @default.
• W2742460075 hasConcept C71924100 @default.
• W2742460075 hasConcept C90924648 @default.
• W2742460075 hasConceptScore W2742460075C126322002 @default.
• W2742460075 hasConceptScore W2742460075C143998085 @default.
• W2742460075 hasConceptScore W2742460075C2778019345 @default.
• W2742460075 hasConceptScore W2742460075C2778822529 @default.
• W2742460075 hasConceptScore W2742460075C2779134260 @default.
• W2742460075 hasConceptScore W2742460075C2779984678 @default.
• W2742460075 hasConceptScore W2742460075C2780073493 @default.
• W2742460075 hasConceptScore W2742460075C71924100 @default.
• W2742460075 hasConceptScore W2742460075C90924648 @default.
• W2742460075 hasIssue "42" @default.
• W2742460075 hasLocation W27424600751 @default.
• W2742460075 hasLocation W27424600752 @default.
• W2742460075 hasLocation W27424600753 @default.
• W2742460075 hasLocation W27424600754 @default.
• W2742460075 hasLocation W27424600755 @default.
• W2742460075 hasOpenAccess W2742460075 @default.
• W2742460075 hasPrimaryLocation W27424600751 @default.
• W2742460075 hasRelatedWork W2609170905 @default.
• W2742460075 hasRelatedWork W2742460075 @default.
• W2742460075 hasRelatedWork W2752827782 @default.
• W2742460075 hasRelatedWork W2765712373 @default.
• W2742460075 hasRelatedWork W2766588635 @default.
• W2742460075 hasRelatedWork W2800070801 @default.
• W2742460075 hasRelatedWork W2999710862 @default.
• W2742460075 hasRelatedWork W4210430352 @default.
• W2742460075 hasRelatedWork W4240236077 @default.
• W2742460075 hasRelatedWork W4251581028 @default.
• W2742460075 hasVolume "8" @default.
• W2742460075 isParatext "false" @default.
• W2742460075 isRetracted "false" @default.
• W2742460075 magId "2742460075" @default.
• W2742460075 workType "article" @default.